Future oncology最新文献_第5页

Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRAS^G12C mutations. KRYSTAL-12研究结果的简明语言总结：阿达格拉西用于KRASG12C突变的非小细胞肺癌。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-09-16 DOI: 10.1080/14796694.2026.2719409

Fabrice Barlesi, Wenxiu Yao, Michaël Duruisseaux, Ludovic Doucet, Aitor Azkárate Martínez, Vanesa Gregorc, Oscar Juan-Vidal, Shun Lu, Charlotte De Bondt, Filippo de Marinis, Helena Linardou, Young-Chul Kim, Robert Jotte, Enriqueta Felip, Giuseppe Lo Russo, Martin Reck, Mary F MichenzIe, Wenjing Yang, Julie N Meade, Beata Korytowsky, Tony S K Mok

引用次数: 0

Efficacy analysis of first-line chemoimmunotherapy with or without radiotherapy in stage IVB esophageal squamous cell carcinoma: a real-world study. 一线化疗免疫治疗伴或不伴放疗治疗IVB期食管鳞状细胞癌的疗效分析：一项真实世界的研究。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-07-27 DOI: 10.1080/14796694.2026.2701482

Yanhui Zhang, Yuqin Jin, Ruidan Zhang, Junfeng Zhao, Baosheng Li

{"title":"Efficacy analysis of first-line chemoimmunotherapy with or without radiotherapy in stage IVB esophageal squamous cell carcinoma: a real-world study.","authors":"Yanhui Zhang, Yuqin Jin, Ruidan Zhang, Junfeng Zhao, Baosheng Li","doi":"10.1080/14796694.2026.2701482","DOIUrl":"10.1080/14796694.2026.2701482","url":null,"abstract":"Background: This study assessed whether adding radiotherapy (RT) to first-line chemoimmunotherapy (ICT) improves outcomes in stage IVB esophageal squamous cell carcinoma (ESCC), given the limited benefit of ICT alone.Methods: After 1:1 propensity score matching, 280 patients with stage IVB ESCC were included, with 140 receiving ICT plus RT (ICRT) and 140 receiving ICT alone.Results: ICRT significantly prolonged progression-free survival (12.97 vs. 8.17 months; HR = 0.61, p < 0.001) and overall survival (25.27 vs. 18.77 months; HR = 0.63, p = 0.012) compared with ICT alone. Concurrent and sequential RT showed no significant survival difference in this post hoc analysis. Patients with non-regional lymph node metastases and those receiving RT doses ≥60 Gy showed greater PFS benefit. However, severe hematologic toxicity, particularly lymphopenia (30.71% vs. 3.57%), was more common with ICRT.Conclusion: Adding RT to ICT improved survival in stage IVB ESCC. Despite increased toxicity, overall safety was manageable.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2221-2231"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synthetic lethality targets in pancreatic ductal adenocarcinoma: prevalence and limitations of liquid biopsy detection in a minority-serving cancer center. 胰腺导管腺癌的合成致死靶点：液体活检检测在少数民族癌症中心的患病率和局限性

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-07-09 DOI: 10.1080/14796694.2026.2699426

Mahmoud Abdelsamia, Yafang Li, Daniel Eastwood, Ian Rabinowitz

{"title":"Synthetic lethality targets in pancreatic ductal adenocarcinoma: prevalence and limitations of liquid biopsy detection in a minority-serving cancer center.","authors":"Mahmoud Abdelsamia, Yafang Li, Daniel Eastwood, Ian Rabinowitz","doi":"10.1080/14796694.2026.2699426","DOIUrl":"10.1080/14796694.2026.2699426","url":null,"abstract":"Aims: Synthetic lethality (SL) exploits genetic vulnerabilities in cancer cells, offering therapeutic opportunities beyond conventional targets. While BRCA/poly(ADP-ribose) polymerase (PARP) inhibition is FDA-approved for pancreatic ductal adenocarcinoma (PDAC), the prevalence of other actionable SL targets remains poorly characterized.Patients and methods: We retrospectively analyzed 260 PDAC patients at the University of New Mexico Comprehensive Cancer Center (2017-2022); 74 underwent somatic sequencing (54 tissue, 17 liquid biopsy) and 117 underwent germline testing. The cohort included 11% Native American patients. We characterized eight SL gene targets and compared mutation detection between biopsy methods.Results: TP53 mutations were identified in 73% of patients and CDKN2A was the most prevalent SL target (46%), followed by SMAD4 (24%), MTAP (15%), and ARID1A (14%). Liquid biopsy significantly underdetected key alterations: KRAS detection decreased from 93% (tissue) to 47% (liquid, p < 0.001) and SMAD4 from 33% to 0% (p = 0.004). Native American patients showed significantly lower TP53 mutations than White patients (38% vs 79%, p = 0.023).Conclusions: Multiple SL targets beyond BRCA exist in PDAC. Liquid biopsy inadequately detects critical alterations, particularly deletions. Native American patients demonstrated preliminary molecular differences warranting validation in larger studies. Tissue-based molecular profiling will be essential for comprehensive patient selection as SL-targeted therapies advance.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2179-2188"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy. 预后但不能预测：雄激素受体表达在乳腺癌患者接受新辅助化疗的临床意义。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-06-30 DOI: 10.1080/14796694.2026.2696936

Çiğdem Öztürk, Gamze Usul, Bayram Şen, Recep Bedir, Oğuzhan Okcu

{"title":"Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy.","authors":"Çiğdem Öztürk, Gamze Usul, Bayram Şen, Recep Bedir, Oğuzhan Okcu","doi":"10.1080/14796694.2026.2696936","DOIUrl":"10.1080/14796694.2026.2696936","url":null,"abstract":"Background: The androgen receptor (AR) is a potential biomarker in breast cancer (BC), but its predictive and prognostic value-especially regarding neoadjuvant chemotherapy (NAC) response-remains unclear. This study evaluates the relationship between pre-treatment AR expression and both therapeutic response and survival outcomes.Methods: A retrospective multicenter cohort of 194 BC patients treated with NAC was analyzed. AR expression was assessed by immunohistochemistry on pretreatment core biopsy samples. Associations between AR expression and clinicopathologic variables, pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS) were statistically evaluated.Results: AR expression was significantly associated with hormone receptor positivity and lower tumor grade. However, no significant relationship was found between AR expression and pCR in the overall cohort or within molecular subtypes. Although AR-positive patients exhibited longer OS in univariate analysis (p = 0.024), this association was not sustained in multivariate models.Conclusion: Although AR expression correlates with favorable clinicopathologic features in BC patients undergoing NAC, it is not an independent predictor of pathological response or long-term survival outcomes. A key limitation is the analysis of the entire cohort together; given the contrasting biological roles of AR across different molecular subtypes, future studies should evaluate TNBC and Luminal tumors separately.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2213-2220"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. TroFuse-011研究设计：sacituzumab替鲁莫替康联合或不联合派姆单抗治疗PD-L1 CPS <10的晚期三阴性乳腺癌。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-07-31 DOI: 10.1080/14796694.2026.2701483

Hope S Rugo, Peter Schmid, Javier Cortes, Toshimi Takano, Peter A Fasching, Yeon Hee Park, Giampaolo Bianchini, Sandra Ximena Franco, Cynthia Villarreal-Garza, Olivier Tredan, Yongmei Yin, Romualdo Barroso-Sousa, Xuan Peng, Usha Malhotra, Karen Lisa Smith, Aditya Bardia

{"title":"TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.","authors":"Hope S Rugo, Peter Schmid, Javier Cortes, Toshimi Takano, Peter A Fasching, Yeon Hee Park, Giampaolo Bianchini, Sandra Ximena Franco, Cynthia Villarreal-Garza, Olivier Tredan, Yongmei Yin, Romualdo Barroso-Sousa, Xuan Peng, Usha Malhotra, Karen Lisa Smith, Aditya Bardia","doi":"10.1080/14796694.2026.2701483","DOIUrl":"10.1080/14796694.2026.2701483","url":null,"abstract":"Patients with advanced TNBC with PD-L1 CPS < 10 are typically treated with chemotherapy and experience poor outcomes. Sacituzumab tirumotecan (sac-TMT; MK-2870/SKB264) is a trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate with a unique, bifunctional linker that maximizes payload delivery to tumor cells. Combining sac-TMT with immunotherapy may improve outcomes given their complementary respective direct cytotoxic and immune-mediated antitumor effects regardless of tumor PD-L1 expression. The TroFuse-011 study evaluates sac-TMT with/without pembrolizumab versus treatment of physician's choice (TPC; paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin) in previously untreated, centrally confirmed, locally recurrent unresectable or metastatic TNBC with PD-L1 CPS <10. Eligible adults with measurable disease per RECIST version 1.1, ECOG PS 0/1, and tumor tissue sample for central PD-L1 and TROP2 testing will be randomized to receive sac-TMT (arm A), sac-TMT plus pembrolizumab (arm B), or TPC (arm C). Primary endpoints include progression-free survival (PFS; arm A vs C and arm B vs C) and overall survival (OS; arm A vs C). Secondary endpoints include PFS (arm B vs A), OS (arm B vs C and arm B vs A), objective response rate (arm A vs C and arm B vs C), duration of response, patient-reported outcomes, and safety. Enrollment is ongoing.Clinical trial registration: www.clinicaltrials.gov identifier is NCT06841354.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2121-2129"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences. 阴燃型多发性骨髓瘤：一项关于疾病认知和患者治疗偏好的多国混合方法研究。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-08-04 DOI: 10.1080/14796694.2026.2710562

Matthew Quaife, Cecilia Jimenez-Moreno, Blanca Gros Otero, Aisha Asra, Niodita Gupta-Werner, Katharine S Gries, Marie-Kristin Leisten, Kathryn Matt, Robin Carson, Robyn Dennis, Jianming He, Bennett Levitan, Sacheeta Bathija

{"title":"Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences.","authors":"Matthew Quaife, Cecilia Jimenez-Moreno, Blanca Gros Otero, Aisha Asra, Niodita Gupta-Werner, Katharine S Gries, Marie-Kristin Leisten, Kathryn Matt, Robin Carson, Robyn Dennis, Jianming He, Bennett Levitan, Sacheeta Bathija","doi":"10.1080/14796694.2026.2710562","DOIUrl":"10.1080/14796694.2026.2710562","url":null,"abstract":"Aims: To understand disease perceptions and treatment preferences of patients with high-risk smoldering multiple myeloma (HR-SMM) or multiple myeloma (MM) that recently progressed from HR-SMM, and to estimate the minimum progression-free survival (min-PFS) required to accept the treatment burden.Methods: This mixed-methods study interviewed 50 patients (HR-SMM and MM 1:1) from the USA, France, Italy, and Spain. Qualitative semi-structured interviews explored symptoms, quality of life, and awareness and expectations of SMM treatments. A quantitative thresholding exercise elicited the min-PFS for patients to accept a hypothetical treatment. Results were reported for HR-SMM and MM.Results: The most common symptoms were fatigue (68%) and pain (56%); 20% were asymptomatic. Most treatment-naïve patients (n = 31/44) accepted physician recommendations that treatment was not needed, burdensome, or not available. Twenty-three patients (61%) were willing to start treatment while having HR-SMM. Patients expected treatments to delay disease progression (30%) or increase life expectancy (24%), whereas 22% expected to be \"cured\" if treated. The min-PFS for the given treatment was 60 months; 61 and 59 months for HR-SMM and MM, respectively.Conclusions: Considerable psychological, physical, and functional burdens were imposed on HR-SMM patients by potential disease progression. Most patients were willing to receive treatment to delay progression and reduce symptomatic burden.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2299-2311"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting breast cancer pathological complete response with clinical and imaging data. 通过临床和影像学资料预测乳腺癌病理完全缓解。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-07-18 DOI: 10.1080/14796694.2026.2706356

Xinlong Tao, Yongxin Li, Yinyin Ye, Xiao Liang, Xingchang Qiu, Jiuda Zhao

{"title":"Predicting breast cancer pathological complete response with clinical and imaging data.","authors":"Xinlong Tao, Yongxin Li, Yinyin Ye, Xiao Liang, Xingchang Qiu, Jiuda Zhao","doi":"10.1080/14796694.2026.2706356","DOIUrl":"10.1080/14796694.2026.2706356","url":null,"abstract":"Introduction: Pathological complete response (pCR) is a key prognostic indicator in breast cancer (BC) patients receiving neoadjuvant chemotherapy (NAC). Unimodal prediction models are limited, underscoring the need for multimodal machine learning approaches.Methods: This retrospective study included 211 BC patients. A radiomics score (Radscore) was developed from multiparametric MRI, and integrated with clinical predictors using machine learning to build three models: clinical, radiomics, and a combined clinical-radiomics model. Their performance was systematically compared.Results: The combined clinical-radiomics model significantly outperformed unimodal models, with an AUC of 0.937 in the training cohort and 0.853 in the validation cohort. Decision curve and calibration analyses suggested potential clinical utility and accuracy.Conclusion: The clinical-radiomics model accurately predicts pCR to NAC in BC, surpassing unimodal methods. Its dynamic nomogram aids in personalizing treatment decisions.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2261-2270"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540178/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries. 复发/难治性边缘带淋巴瘤的治疗模式：来自7个国家的真实世界证据

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-07-30 DOI: 10.1080/14796694.2026.2700479

Harshali Patel, Lynn Huynh, Patrick Squires, Jennifer Prescott, Katherine Ryland, Maryaline Catillon, Tracy Guo, Kelvin Tamakloe, Steven Liu, Mei Sheng Duh, Monika Raut, Craig A Portell

{"title":"Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries.","authors":"Harshali Patel, Lynn Huynh, Patrick Squires, Jennifer Prescott, Katherine Ryland, Maryaline Catillon, Tracy Guo, Kelvin Tamakloe, Steven Liu, Mei Sheng Duh, Monika Raut, Craig A Portell","doi":"10.1080/14796694.2026.2700479","DOIUrl":"10.1080/14796694.2026.2700479","url":null,"abstract":"Background: Given the rarity of marginal zone lymphoma (MZL), real-world data on relapsed/refractory (R/R) MZL are limited.Methods: This retrospective panel-based chart review study examined patient characteristics and treatment patterns among patients with R/R MZL who received a second or third line (2L or 3L) of therapy between 1 January 2014 and 31 December 2021 in 7 countries. Treatment patterns were summarized overall and by MZL type.Results: The study included 526 patients, 513 with 2L and 13 with 3L as index treatment. The median age of 2L patients was 67.0 years. Most patients had stage III or IV disease and intermediate or high-risk prognostic scores. Around 60.0% of the patients had nodal, 22.8% had splenic, and 14.2% had mucosa-associated lymphoid tissue (MALT) MZL. Most patients received chemoimmunotherapy (42.8%), Bruton's tyrosine kinase inhibitors (BTKi; 25.1%), or lenalidomide and rituximab/obinutuzumab (16.3%) in 2L. Treatment patterns varied across subtypes, with notable differences in 2L BTKi use.Conclusions: These findings suggest variability and limitations in the treatment selection for R/R MZL beyond frontline therapy, with the choice of treatment mostly limited to chemoimmunotherapy and BTKi. This study provides much-needed real-world evidence that can help guide clinical management and the development of novel therapies.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2201-2211"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148630074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study. 中国早期乳腺癌患者蒽环类药物引起心脏毒性的临床和遗传危险因素：一项候选基因研究

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-08-04 DOI: 10.1080/14796694.2026.2713355

Shan Xu, Hao Yang, Nan Hu

{"title":"Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study.","authors":"Shan Xu, Hao Yang, Nan Hu","doi":"10.1080/14796694.2026.2713355","DOIUrl":"10.1080/14796694.2026.2713355","url":null,"abstract":"Purpose: This study aimed to clarify the incidence of anthracycline-induced cardiotoxicity (ACT) and identify its clinical and candidate genetic risk factors in Chinese early-stage breast cancer patients, so as to provide evidence for clinical risk assessment and individualized cardiac protection.Methods: This study included 119 patients who received anthracycline-based chemotherapy. Cardiac function was assessed via echocardiography at baseline, post-chemotherapy, and at one-year follow-up. Five candidate SNPs (CBR3 rs1056892, GSTP1 rs1695, SLC28A3 rs7853758, ABCB1 rs1045642, ABCC2 rs8187710) were genotyped to analyze their association with ACT.Results: The incidence of ACT was 15.1% (18/119). No significant association was found between any of the five genotyped SNPs and the development of ACT (all p > 0.05). Multivariate logistic regression analysis identified older age, higher cumulative anthracycline dose, and the use of HER2-targeted antibodies (trastuzumab/pertuzumab) as independent clinical risk factors for ACT.Conclusion: In Chinese early-stage breast cancer patients, ACT is significantly associated with clinical risk factors rather than the selected candidate genetic polymorphisms. These findings support targeted cardiac monitoring and optimized treatment strategies for high-risk patients to reduce the occurrence of anthracycline-related cardiac injury.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2313-2321"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors. TANGENT研究设计：emactuzumab治疗腱鞘巨细胞瘤的III期随机研究。

IF 3.1 4区医学

Future oncology Pub Date : 2026-08-01 Epub Date: 2026-07-20 DOI: 10.1080/14796694.2026.2702768

Hans Gelderblom, Emanuela Palmerini, Michiel van de Sande, Javier Martin-Broto, Gabriel Tinoco, Elyse Seltzer, Madhu Davies, Ruth Coll, Sander Veltkamp, Jean-Yves Blay

{"title":"TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.","authors":"Hans Gelderblom, Emanuela Palmerini, Michiel van de Sande, Javier Martin-Broto, Gabriel Tinoco, Elyse Seltzer, Madhu Davies, Ruth Coll, Sander Veltkamp, Jean-Yves Blay","doi":"10.1080/14796694.2026.2702768","DOIUrl":"10.1080/14796694.2026.2702768","url":null,"abstract":"Tenosynovial giant cell tumors (TGCT) are rare, locally aggressive neoplasms causing pain, stiffness, swelling, limited range of motion, and joint degeneration, which can be debilitating. Therapeutic options include surgery or systemic therapy with colony-stimulating factor 1 receptor (CSF-1R) pathway inhibitors. However, many are not amenable to surgery or have high postsurgical recurrence rates. Available systemic therapies require long-term administration and can have burdensome side effects. Emactuzumab is a novel, potent, CSF-1R inhibiting monoclonal antibody with a unique mechanism of action targeting the receptor dimerization interface of the CSF-1R to reduce tumor-associated macrophages and inflammation within the TGCT microenvironment. It is the only short-course, intravenous therapy in development for TGCT. In a phase I study, emactuzumab resulted in robust and durable responses, and a manageable safety profile in patients with TGCT, supporting further research as a treatment option to address unmet need and improve quality of life in patients with TGCT. TANGENT is a randomized, double-blind, global, phase III study (NCT05417789) to investigate the safety and efficacy of intravenous emactuzumab versus placebo in patients with TGCT not amenable to surgery.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05417789 initially registered on 1 June 2022.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2109-2119"},"PeriodicalIF":3.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13436830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0